首页 › 基金 › Soleus Capital Management, L.P. › AVLN
Soleus Capital Management, L.P. 对 AVLN 的持仓历史
AVALYN PHARMACEUTICALS INC · 医疗保健
Soleus Capital Management, L.P. 在 Q3 2026 的 13F 申报中披露持有 AVLN(AVALYN PHARMACEUTICALS INC)1,019,000 股,市值约 US$29.0M,约占其申报组合的 1.03%,在其申报持仓中市值排名第 24 位。 Soleus Capital Management, L.P. 最近 2 个申报季度中有 2 个季度披露了 AVLN 持仓,最早可追溯至 Q2 2026。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Soleus Capital Management, L.P. 对 AVLN 的持仓演变
Soleus Capital Management, L.P. 于 Q2 2026 首次披露 AVLN 持仓:419,000 股(约 US$13.8M)。 该持仓在 Q3 2026 达到峰值 1,019,000 股,市值约 US$29.0M。 在 2 次申报中,Soleus Capital Management, L.P. 1 次增持、0 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 1,019,000 股、市值约 US$29.0M,环比增持 600,000 股。。 持仓曾出现大幅变动:Q3 2026 增持约 143% (随后一个季度股价上涨 4%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2026 | 419.00K | $13.79M | 新进 |
| Q3 2026 | 1.02M | $29.03M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 AVLN 与 13F 数据
AVLN(AVALYN PHARMACEUTICALS INC)属于医疗保健行业。我们追踪的基金中还有 114 只申报持有 AVLN,申报仓位最大的包括:Novo Holdings A/S (US$98.3M), SR ONE CAPITAL MANAGEMENT, LP (US$94.3M), PERCEPTIVE ADVISORS LLC (US$76.2M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 AVLN 的基金
- Novo Holdings A/S 3.45M 股 · $98.27M · Q3 2026
- SR ONE CAPITAL MANAGEMENT, LP 3.31M 股 · $94.26M · Q3 2026
- PERCEPTIVE ADVISORS LLC 2.68M 股 · $76.22M · Q3 2026
- MONTANOVA CAPITAL, LLC 2.50M 股 · $71.31M · Q3 2026
- NVP Associates, LLC 2.27M 股 · $64.63M · Q3 2026
- Catalio Capital Management, LP 1.70M 股 · $48.40M · Q3 2026
- Bellevue Group AG 1.35M 股 · $38.46M · Q3 2026
- Andera Partners 929.82K 股 · $26.49M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 866.79K 股 · $24.69M · Q3 2026
- TPG GP A, LLC 773.07K 股 · $22.02M · Q3 2026
- BRAIDWELL LP 744.46K 股 · $21.21M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 731.00K 股 · $20.83M · Q3 2026
更多关于 Soleus Capital Management, L.P.
常见问题
How long has Soleus Capital Management, L.P. held AVLN?
Soleus Capital Management, L.P. has disclosed AVLN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Soleus Capital Management, L.P.'s current position in AVLN?
As of Q3 2026, Soleus Capital Management, L.P. holds 1.02M shares of AVLN (AVALYN PHARMACEUTICALS INC), valued at $29.03M, representing 1.03% of its reported portfolio and ranking #24.
Has Soleus Capital Management, L.P. been buying or selling AVLN?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. increased its position in AVLN. The position peaked in Q3 2026 at 1.02M shares.
Which other funds hold AVLN?
Other major institutional holders of AVLN include Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, among 114 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.